REG - CelLBxHealth PLC - Confirmation of Q1 trading update

CellbxhealthAnnouncement

Thu 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260430:nRSd4838Ca&default-theme=true

RNS Number : 4838C  CelLBxHealth PLC  30 April 2026

 

CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

 

Confirmation of Q1 trading update

 

Guildford, UK and Plymouth Meeting, U.S. - 30 April 2026 - CelLBxHealth plc
(AIM: CLBX), a CTC intelligence company specialising in innovative circulating
tumor cell (CTC) solutions for use in research, drug development and clinical
oncology, announces that it will provide a trading update for Q1 2026 in
mid-May.

 

For further information:

 

 CelLBxHealth plc                                investor@cellbxhealth.com (mailto:investor@cellbxhealth.com)

 Peter Collins, Chief Executive Officer          via Walbrook PR

 Jan Groen, Executive Chairman

 Cavendish (NOMAD and Broker)                    +44 (0)20 7220 0500

 Geoff Nash / Isaac Hooper (Corporate Finance)

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Investor and Media Relations)      Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

                                               (mailto:CelLBx@walbrookpr.com)
 Paul McManus / Alice Woodings

                                                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative
circulating tumor cell (CTC) solutions for use in research, drug development
and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs
from blood and can be integrated with existing laboratory instruments for
comprehensive downstream analysis - including whole-cell imaging, proteomic
profiling and full genomic workflows.

 

Commercial focus span three revenue streams - Product Sales of the Parsortix
platform and consumables through CRO and clinical lab partnerships, Laboratory
Services including clinical trial support and assay development delivered from
a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through
a combination of strategic partnerships and in-house development.

 

For more information, visit https://cellbxhealth.com/
(https://cellbxhealth.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAFLNAAFKEAA



            Copyright 2019 Regulatory News Service, all rights reserved